Roche Announces Updates on Retinal Vein Occlusion (RVO) for Vabysmo

TOKYO, October 10, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding long-term results of its two phase III clinical trials (BALATON study and COMINO study) for Vabysmo ® (faricimab) for retinal vein occlusion (RVO). Please refer to the link below for details of the press release: Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies https://www.roche.com/media/releases/med-cor-2023-10-10

The release as fetched from its publisher. chugai-pharm.co.jp ↗